Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma
Author:
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference18 articles.
1. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma;Molina;Clin Genitourin Cancer,2008
2. New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview;Motzer;Oncologist,2011
3. Update on targeted therapies for clear renal cell carcinoma;Singer;Curr Opin Oncol,2011
4. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence;Hutson;Oncologist,2011
5. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow;Molina;Oncologist,2011
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current and Emerging Treatments for Metastatic Renal Cell Carcinoma;Current Cancer Drug Targets;2018-05-22
2. Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib;OncoTargets and Therapy;2017-10
3. Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers;Future Oncology;2017-06
4. Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA;International Journal of Urology;2017-03-02
5. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies;Clinical Genitourinary Cancer;2016-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3